Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Esperion. The associated price target remains the same with $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Esperion’s strong commercial execution and strategic global expansion. The company has demonstrated consistent growth, with a significant increase in U.S. product revenue for NEXLETOL and NEXLIZET, driven by a rise in retail prescriptions. This growth is supported by robust market access and payer coverage, ensuring that over 90% of commercial lives in the U.S. have access to these products.
Additionally, Esperion has taken strategic steps to mitigate competition risks by reaching settlements to delay the launch of generic versions of its products until 2040. The company’s global expansion efforts are also noteworthy, with recent approvals in Japan and favorable recommendations in Europe, which are expected to trigger milestone payments and further regulatory filings. Furthermore, Esperion’s focus on pipeline innovation, such as the development of a new ACL inhibitor, positions the company for sustained profitability and long-term growth.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESPR in relation to earlier this year.